Altitude Life Science Ventures

Lila Sciences is a technology company specializing in AI-driven platforms for scientific research. It focuses on life, chemical, and materials sciences, developing tools and autonomous labs to streamline research and facilitate discoveries. The company's platform uses generative AI to process vast amounts of data, design experiments, generate hypotheses, and test them in real-world environments, thereby accelerating scientific breakthroughs and enabling rapid innovation.

Vilya is a biotechnology company focused on developing innovative drugs that specifically target the biology of diseases. The company employs a unique platform that explores uncharted chemical space to design new molecular structures, which are intermediate in size between small molecules and antibodies. These structures possess essential drug-like properties, such as the capacity to traverse biological membranes and disrupt protein-protein interactions. By leveraging advanced computing techniques, Vilya aims to make traditional high throughput screening methods obsolete, ultimately working towards the creation of new medicines that can effectively treat a range of diseases.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

CERo Therapeutics, Inc. is a biotechnology company based in San Francisco, California, focused on advancing cellular immunotherapy. Established in 2016, the company has developed a hybrid platform that merges innate and adaptive immune responses to create engineered T-cell therapeutics for cancer treatment. This proprietary approach aims to harness the body's complete immune capabilities to enhance the effectiveness of cancer therapies. By integrating desirable features from both immune systems, CERo Therapeutics seeks to optimize treatment outcomes for patients with cancer.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, focused on developing innovative inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, which stands for inhaled Small Particles Easily Respirable and Emitted, Pulmatrix aims to enhance the delivery of therapeutic agents directly to the lungs while minimizing systemic side effects. The company's product pipeline includes Pulmazole, an inhaled anti-fungal targeting allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor designed for obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). Established in 2003, Pulmatrix collaborates with various partners, including RespiVert Ltd. and Cipla Technologies LLC, to advance its drug candidates and address significant unmet medical needs in respiratory care.

Receptos, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the discovery and development of therapeutics for immune disorders. The company’s lead product, ozanimod, is an oral therapy currently undergoing phase III trials for relapsing multiple sclerosis and phase II trials for ulcerative colitis and Crohn's disease. Additionally, Receptos is developing RPC4046, a monoclonal antibody in phase II trials for eosinophilic esophagitis, an allergic and immune-mediated condition. The company is also engaged in research on glucagon-like peptide-1 receptor small molecule positive allosteric modulators, which are in preclinical studies for treating Type 2 diabetes. Founded in 2008, Receptos was initially known as Receptor Pharmaceuticals, Inc. and rebranded in May 2009. As of August 2015, Receptos operates as a subsidiary of Celgene Corporation.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel sectors. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, which is a more abundant and cost-effective resource than oil. The company's technology allows for the conversion of natural gas and low-value by-products into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel. Siluria's research and development teams are actively working towards commercializing their technology through partnerships with leading chemical and fuel companies, facilitating pilot-scale production to integrate their innovations into existing industry infrastructure.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel sectors. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, which is a more abundant and cost-effective resource than oil. The company's technology allows for the conversion of natural gas and low-value by-products into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel. Siluria's research and development teams are actively working towards commercializing their technology through partnerships with leading chemical and fuel companies, facilitating pilot-scale production to integrate their innovations into existing industry infrastructure.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel sectors. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, which is a more abundant and cost-effective resource than oil. The company's technology allows for the conversion of natural gas and low-value by-products into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel. Siluria's research and development teams are actively working towards commercializing their technology through partnerships with leading chemical and fuel companies, facilitating pilot-scale production to integrate their innovations into existing industry infrastructure.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Limerick BioPharma focuses on creating innovative pharmaceutical compounds designed to enhance the efficacy of existing and experimental drugs, while reducing harmful side effects on non-targeted organs and tissues. The company aims to improve patient quality of life by developing adjunctive therapies that work in conjunction with other medications. Additionally, Limerick BioPharma is advancing novel treatments for metabolic diseases, specifically targeting conditions like hypercholesteremia and hyperglycemia. They employ advanced methodologies to simulate blood-tissue barrier activity both in laboratory settings and in living organisms, positioning them at the forefront of research in metabolic disorders and solid organ transplantation.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

Limerick BioPharma focuses on creating innovative pharmaceutical compounds designed to enhance the efficacy of existing and experimental drugs, while reducing harmful side effects on non-targeted organs and tissues. The company aims to improve patient quality of life by developing adjunctive therapies that work in conjunction with other medications. Additionally, Limerick BioPharma is advancing novel treatments for metabolic diseases, specifically targeting conditions like hypercholesteremia and hyperglycemia. They employ advanced methodologies to simulate blood-tissue barrier activity both in laboratory settings and in living organisms, positioning them at the forefront of research in metabolic disorders and solid organ transplantation.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.